Eyegate Pharmaceuticals Inc (EYEG) Trading Down 8.6%
Shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) were down 8.6% during trading on Thursday . The stock traded as low as $2.01 and last traded at $2.13, with a volume of 51,324 shares changing hands. The stock had previously closed at $2.33.
Several analysts recently commented on EYEG shares. Noble Financial started coverage on shares of Eyegate Pharmaceuticals in a research report on Thursday, April 7th. They set a “buy” rating and a $10.00 price target on the stock. Rodman & Renshaw restated a “buy” rating on shares of Eyegate Pharmaceuticals in a research report on Thursday, May 12th. Maxim Group restated a “hold” rating on shares of Eyegate Pharmaceuticals in a research report on Tuesday, June 28th. Finally, Chardan Capital restated a “buy” rating on shares of Eyegate Pharmaceuticals in a research report on Thursday, April 14th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $9.00.
The stock’s 50-day moving average is $2.64 and its 200-day moving average is $2.98. The company’s market cap is $16.86 million.
In other news, Director Morton Goldberg sold 10,939 shares of the business’s stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $3.31, for a total transaction of $36,208.09. Following the completion of the sale, the director now owns 43,216 shares in the company, valued at approximately $143,044.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Ventech Capital Ii sold 28,600 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $3.04, for a total transaction of $86,944.00. Following the sale, the insider now owns 1,608,973 shares of the company’s stock, valued at approximately $4,891,277.92. The disclosure for this sale can be found here.
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.